Regencell Bioscience Holdings Limited (RGC)

RGC Balance Sheet

Financials in millions USD. Fiscal year is July - June.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Cash & Equivalents	2.96	1.56	6.42	0.06	0.39
Short-Term Investments	5	10	10	-	-
Cash & Short-Term Investments	7.96	11.56	16.42	0.06	0.39
Cash Growth	-31.16%	-29.56%	27532.00%	-84.65%	59.05%
Prepaid Expenses	0.15	0.06	0.03	0.01	-
Total Current Assets	8.11	11.62	16.44	0.07	0.39
Property, Plant & Equipment	0.23	0.89	1.46	0.08	0.11
Long-Term Deferred Charges	-	-	-	0.17	-
Other Long-Term Assets	0.1	0.11	0.11	0.02	0.02
Total Assets	8.44	12.62	18.02	0.34	0.51
Accrued Expenses	0.13	0.16	0.15	0.57	0.1
Short-Term Debt	-	-	-	3.68	3.07
Current Portion of Leases	0.06	0.44	0.41	-	-
Other Current Liabilities	0.01	0.01	0.02	0.08	-
Total Current Liabilities	0.19	0.61	0.58	4.34	3.16
Long-Term Leases	0.03	0.03	0.36	-	-
Total Liabilities	0.22	0.63	0.94	4.34	3.16
Common Stock	0	0	0	0	0
Additional Paid-In Capital	29.88	29.43	28.51	0	0
Retained Earnings	-21.62	-17.32	-11.44	-4	-2.65
Comprehensive Income & Other	-0.05	-0.09	-	-	-
Total Common Equity	8.22	12.03	17.07	-4	-2.65
Minority Interest	-	-0.04	0.02	-	-
Shareholders' Equity	8.22	11.99	17.08	-4	-2.65
Total Liabilities & Equity	8.44	12.62	18.02	0.34	0.51
Total Debt	0.09	0.46	0.77	3.68	3.07
Net Cash (Debt)	7.88	11.1	15.65	-3.62	-2.68
Net Cash Growth	-29.06%	-29.05%	-	-	-
Net Cash Per Share	0.61	0.85	1.22	-0.36	-0.27
Filing Date Shares Outstanding	13.01	13.01	13.01	10	10
Total Common Shares Outstanding	13.01	13.01	13.01	10	10
Working Capital	7.92	11.01	15.87	-4.27	-2.78
Book Value Per Share	0.63	0.92	1.31	-0.40	-0.27
Tangible Book Value	8.22	12.03	17.07	-4	-2.65
Tangible Book Value Per Share	0.63	0.92	1.31	-0.40	-0.27
Machinery	0.3	0.3	0.3	-	-
Leasehold Improvements	0.62	0.62	0.6	0.12	0.12

Updated Oct 25, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q